Toggle

A drug, iptacopan, to treat paroxysmal nocturnal hemoglobinuria (PNH) in children and teens 

Print

2 - 18

Phase 3

2 Locations

NCT06934967

Clinical Trial Goal


To find out if iptacopan is safe and works well to treat PNH in children and teens 

You may be able to join this trial if you:


Your child:
  • Is 2 - 18 years old
  • Has PNH
  • Have not had a blood or marrow transplant (BMT) in the last 1 year
  • You agree to have other standard tests done to see if your child can be in the clinical trial 

Trial Details


Iptacopan is a small molecule inhibitor of complement factor B. 

Your child will get:
  • Iptacopan – A pill that your child takes by mouth. The dose your child will get depends on when they start the trial and how safe it has been

The clinical trial doctors will check your child's health for up to 1 year.

The Food and Drug Administration (FDA) has approved iptacopan to treat PNH in adults. Using it in this way to treat PNH in children and teens is new and unproven. 

Contacts


Novartis Pharmaceuticals, 1-888-669-6682, novartis.email@novartis.com

Novartis Pharmaceuticals, +41613241111

Locations


Cancer Institute of New JerseyRECRUITING

New Brunswick, New Jersey
Serban Morojanu, +1 732-235-7577, moroiasa@cinj.rutgers.edu

Childrens Hospital of PhiladelphiaRECRUITING

Philadelphia, Pennsylvania
Ariel Rivera, +1 267 425 2136, riveraa12@chop.edu

ClinicalTrials.gov record


NCT06934967. First posted on 4/18/25

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org